A Phase 3 interventional study of Adalimumab in Crohn's Disease, sponsored by AbbVie. Completed. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2016-04-12.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.
Among the 42 studies testing adalimumab in Crohn Disease, this one is the 36th largest by enrollment, is one of 3 that started in 2013, is one of 22 in phase 3, and was the 23rd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18–70
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 15 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 24 · Phase 4 13
First in 2002; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 143 across the 42 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Crohn Disease by AbbVie: 6 open now, 14 under way, 6 of them phase 3. Of 38 finished, 28 (74%) have results posted.
Among the 55 studies in Crohn Disease by AbbVie, this one is the 25th largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2013, is one of 16 in phase 3, and was the 12th registered.
AbbVie’s Crohn Disease studies by the year they started, since 2007.
1 of the studies testing adalimumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing adalimumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy, safety and pharmacokinetics after dose escalation in Japanese subjects with Crohn's Disease.
Subjects who are confirmed to meet all of the inclusion criteria and none of the exclusion criteria during screening period (≤ 21 days) will be given subcutaneous injections of open-label adalimumab 80 mg eow from Week 0 to Week 50. If a subject has an inadequate response at or after Week 8, the subject may be withdrawn from the study. Self-injection of study drug is permitted for the subjects who are willing to perform self-injection, if the investigator decided as appropriate. Disease activity will be evaluated by Crohn's disease activity index (CDAI) at Screening, Week 0 and every 4 weeks until Week 52. Follow-up will be performed at 70 days after the last dose of study drug by visit or telephone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.
Biological: Adalimumab
Adalimumab pre-filled syringe, administered by subcutaneous injection.
Also known as: Humira, ABT-D2E7
Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 8
CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.
Time frame: Week 8
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Every 4 Weeks up to Week 52
CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) Every 4 Weeks up to Week 52
CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used. Week 8 was the primary outcome measure.
Time frame: Weeks 4, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Who Achieved Clinical Response 70 (CR70; Crohn's Disease Activity Index [CDAI] Decrease ≥ 70 From Week 0) Every 4 Weeks up to Week 52
CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Who Achieved Clinical Response 100 (CR100; Crohn's Disease Activity Index [CDAI] Decrease of 100 From Week 0) Every 4 Weeks up to Week 52
CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
C-reactive Protein (CRP): Mean Change From Baseline (Week 0) to Week 52
C-reactive protein (CRP) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 0.3 mg/dL, slightly increasing with age. Last Observation Carried Forward (LOCF) was used for missing data.
Time frame: Baseline (Week 0) and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Number of Participants With Potentially Significant Hematology Parameters
Blood was collected for analysis at designated study visits; hematology results were provided by each site laboratory. The number of participants with an abnormal laboratory result (higher than upper limit of normal \[ULN\] or lower than lower limit of normal \[LLN\]) meeting Common Toxicity Criteria (CTC) of Grade 3 or higher is summarized. Increase is signified by ↑. n=the number of participants with CTC Grade \<3 at baseline and a post-baseline value.
Time frame: 52 weeks
Number of Participants With Potentially Significant Clinical Chemistry Parameters
Blood was collected for analysis at designated study visits; chemistry results were provided by a central laboratory. The number of participants with an abnormal laboratory result (higher than upper limit of normal \[ULN\] or lower than lower limit of normal \[LLN\]) meeting Common Toxicity Criteria (CTC) of Grade 3 or higher is summarized. n=the number of participants with CTC Grade \<3 at baseline and a post-baseline value for each parameter.
Time frame: 52 weeks
Systolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit
Blood pressure was measured while the participant was sitting. n=the number of participants with available data at each time point.
Time frame: Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Diastolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit
Blood pressure was measured while the participant was sitting. n=the number of participants with available data at each time point.
Time frame: Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Heart Rate: Mean Change From Baseline (Week 0) to Each Visit
Heart rate was measured while the participant was sitting. n=the number of participants with available data at each time point.
Time frame: Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Body Temperature: Mean Change From Baseline (Week 0) to Each Visit
n=the number of participants with available data at each time point.
Time frame: Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs or TESAE) are defined as any event that began or worsened in severity after the first dose of study drug. The investigator assessed the relationship of each event to the use of study drug as either Reasonable possibility or No reasonable possibility of being related to study drug. For more details on adverse events please see the AE section below.
Time frame: 60 weeks
Change in Mean Serum Adalimumab Concentration From Baseline (Week 0) to Week 52
Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated heterogeneous electrochemiluminescence (ECL)-immunoassay method. The assay captures adalimumab via biotinylated anti-idiotypic antibody, and detects it via sulfo-tagged TNF-alpha. n=the number of participants with available data at each time point.
Time frame: Baseline (Week 0) to Week 52
Change in Number of Subjects Positive for Anti-Adalimumab Antibodies (AAA) From Baseline to Week 52
Serum samples with adalimumab concentration below 2 μg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 20 ng/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose.
Time frame: Baseline (Week 0) to Week 52
| Milestone | Adalimumab 80 mg |
|---|---|
| Started | 28 |
| Completed | 18 |
| Not completed | 10 |
| Withdrew: Adverse event | 3 |
| Withdrew: Lack of efficacy | 6 |
| Withdrew: Concomitant prohibited medicine for ae | 1 |
CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.
| percentage of participants | Adalimumab 80 mg |
|---|---|
| Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 8 | 75 (55.1 to 89.3) |
CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.
| percentage of participants | Adalimumab 80 mg |
|---|---|
| Week 4 | 14.3 (4.0 to 32.7) |
| Week 8 | 25.0 (10.7 to 44.9) |
| Week 12 | 28.6 (13.2 to 48.7) |
| Week 16 | 32.1 (15.9 to 52.4) |
| Week 20 | 35.7 (18.6 to 55.9) |
| Week 24 | 42.9 (24.5 to 62.8) |
| Week 28 | 35.7 (18.6 to 55.9) |
| Week 32 | 42.9 (24.5 to 62.8) |
| Week 36 | 39.3 (21.5 to 59.4) |
| Week 40 | 39.3 (21.5 to 59.4) |
| Week 44 | 42.9 (24.5 to 62.8) |
| Week 48 | 39.3 (21.5 to 59.4) |
| Week 52 | 35.7 (18.6 to 55.9) |
CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used. Week 8 was the primary outcome measure.
| percentage of participants | Adalimumab 80 mg |
|---|---|
| Week 4 | 67.9 (47.6 to 84.1) |
| Week 12 | 67.9 (47.6 to 84.1) |
| Week 16 | 67.9 (47.6 to 84.1) |
| Week 20 | 67.9 (47.6 to 84.1) |
| Week 24 | 71.4 (51.3 to 86.8) |
| Week 28 | 64.3 (44.1 to 81.4) |
| Week 32 | 71.4 (51.3 to 86.8) |
| Week 36 | 67.9 (47.6 to 84.1) |
| Week 40 | 64.3 (44.1 to 81.4) |
| Week 44 | 60.7 (40.6 to 78.5) |
| Week 48 | 64.3 (44.1 to 81.4) |
| Week 52 | 57.1 (37.2 to 75.5) |
CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.
| percentage of participants | Adalimumab 80 mg |
|---|---|
| Week 4 | 46.4 (27.5 to 66.1) |
| Week 8 | 57.1 (37.2 to 75.5) |
| Week 12 | 64.3 (44.1 to 81.4) |
| Week 16 | 64.3 (44.1 to 81.4) |
| Week 20 | 64.3 (44.1 to 81.4) |
| Week 24 | 67.9 (47.6 to 84.1) |
| Week 28 | 64.3 (44.1 to 81.4) |
| Week 32 | 67.9 (47.6 to 84.1) |
| Week 36 | 64.3 (44.1 to 81.4) |
| Week 40 | 60.7 (40.6 to 78.5) |
| Week 44 | 57.1 (37.2 to 75.5) |
| Week 48 | 60.7 (40.6 to 78.5) |
| Week 52 | 57.1 (37.2 to 75.5) |
CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.
| percentage of participants | Adalimumab 80 mg |
|---|---|
| Week 4 | 32.1 (15.9 to 52.4) |
| Week 8 | 35.7 (18.6 to 55.9) |
| Week 12 | 39.3 (21.5 to 59.4) |
| Week 16 | 46.4 (27.5 to 66.1) |
| Week 20 | 50.0 (30.6 to 69.4) |
| Week 24 | 50.0 (30.6 to 69.4) |
| Week 28 | 42.9 (24.5 to 62.8) |
| Week 32 | 50.0 (30.6 to 69.4) |
| Week 36 | 50.0 (30.6 to 69.4) |
| Week 40 | 57.1 (37.2 to 75.5) |
| Week 44 | 46.4 (27.5 to 66.1) |
| Week 48 | 50.0 (30.6 to 69.4) |
| Week 52 | 46.4 (27.5 to 66.1) |
C-reactive protein (CRP) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 0.3 mg/dL, slightly increasing with age. Last Observation Carried Forward (LOCF) was used for missing data.
| mg/dL | Adalimumab 80 mg |
|---|---|
| Week 4 | -0.570 ± 1.4902 |
| Week 8 | -0.426 ± 1.6072 |
| Week 12 | -0.710 ± 1.6769 |
| Week 16 | -0.923 ± 1.6981 |
| Week 20 | -0.907 ± 1.7532 |
| Week 24 | -0.813 ± 1.7924 |
| Week 28 | -0.833 ± 1.8820 |
| Week 32 | -0.853 ± 2.0507 |
| Week 36 | -0.586 ± 2.3271 |
| Week 40 | -1.008 ± 2.0471 |
| Week 44 | -0.915 ± 2.2324 |
| Week 48 | -0.649 ± 2.5734 |
| Week 52 | -0.570 ± 2.7635 |
Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated heterogeneous electrochemiluminescence (ECL)-immunoassay method. The assay captures adalimumab via biotinylated anti-idiotypic antibody, and detects it via sulfo-tagged TNF-alpha. n=the number of participants with available data at each time point.
| µg/mL | Adalimumab 80 mg |
|---|---|
| Baseline (Week 0) (n=28) | 3.06 ± 2.19 |
| Week 52 (n=18) | 9.47 ± 5.34 |
Serum samples with adalimumab concentration below 2 μg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 20 ng/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose.
| participants | Adalimumab 80 mg |
|---|---|
| Baseline (Week 0) | 3 |
| Week 52 | 4 |
Blood was collected for analysis at designated study visits; hematology results were provided by each site laboratory. The number of participants with an abnormal laboratory result (higher than upper limit of normal \[ULN\] or lower than lower limit of normal \[LLN\]) meeting Common Toxicity Criteria (CTC) of Grade 3 or higher is summarized. Increase is signified by ↑. n=the number of participants with CTC Grade \<3 at baseline and a post-baseline value.
| participants | Adalimumab 80 mg |
|---|---|
| Haemoglobin <8 g/dL (n=27) | 1 |
| Haemoglobin ↑ >4.0 g/dL (n=28) | 0 |
| Platelet Count <5.0x10^4/mcL (n=28) | 0 |
| White Blood Cells <2.0x10^3/mcL (n=28) | 0 |
| Neutrophils <1.0x10^3/mcL(n=28) | 0 |
| Lymphocytes <0.5x10^3/mcL (n=28) | 4 |
Blood was collected for analysis at designated study visits; chemistry results were provided by a central laboratory. The number of participants with an abnormal laboratory result (higher than upper limit of normal \[ULN\] or lower than lower limit of normal \[LLN\]) meeting Common Toxicity Criteria (CTC) of Grade 3 or higher is summarized. n=the number of participants with CTC Grade \<3 at baseline and a post-baseline value for each parameter.
| participants | Adalimumab 80 mg |
|---|---|
| Alanine Aminotransferase >5xULN (n=28) | 0 |
| Aspartate Aminotransferase >5xULN (n=28) | 0 |
| Gamma-glutamyl Transpeptidase >5x ULN (n=28) | 0 |
| Alkaline Phosphatase >5xU/L (n=28) | 0 |
| Total Bilirubin >3xULN (n=28) | 0 |
| Creatine Phosphokinase >5x ULN (n=28) | 1 |
| Creatinine >3xULN or >3xBL (n=28) | 0 |
| Uric Acid >10.0 mg/dL (n=28) | 0 |
| Inorganic Phosphate <2.0 mg/dL (n=28) | 3 |
| Calcium <7.0 mg/dL (n=28) | 1 |
| Calcium >12.5 mg/dL (n=28) | 0 |
| Sodium <130 mEq/L (n=28) | 0 |
| Sodium >155 mEq/L (n=28) | 0 |
| Potassium <3.0 mEq/L (n=27) | 0 |
| Potassium >6.0 mEq/L (n=28) | 0 |
| Non-fasting Glucose <40 mg/dL (n=28) | 0 |
| Non-fasting Glucose >250 mg/dL (n=28) | 0 |
| Albumin <2.0 g/dL (n=28) | 0 |
| Cholesterol >400 mg/dL(n=28) | 0 |
| Triglycerides >500 mg/dL(n=28) | 0 |
| Magnesium <0.9 mg/dL (n=28) | 0 |
| Magnesium >3.0 mg/dL (n=28) | 0 |
Blood pressure was measured while the participant was sitting. n=the number of participants with available data at each time point.
| mm Hg | Adalimumab 80 mg |
|---|---|
| Week 2 (n=28) | -3.9 ± 11.98 |
| Week 4 (n=28) | -2.5 ± 9.41 |
| Week 8 (n=25) | -1.1 ± 9.98 |
| Week 12 (n=21) | -1.3 ± 9.34 |
| Week 16 (n=21) | -0.2 ± 11.72 |
| Week 20 (n=20) | 1.9 ± 12.64 |
| Week 24 (n=20) | 2.0 ± 8.89 |
| Week 28 (n=20) | 0.8 ± 8.91 |
| Week 32 (n=20) | -1.7 ± 7.41 |
| Week 36 (n=20) | -0.5 ± 10.79 |
| Week 40 (n=20) | 2.3 ± 9.55 |
| Week 44 (n=19) | 1.9 ± 14.12 |
| Week 48 (n=19) | 4.6 ± 11.66 |
| Week 52 (n=18) | -0.3 ± 9.41 |
Blood pressure was measured while the participant was sitting. n=the number of participants with available data at each time point.
| mm Hg | Adalimumab 80 mg |
|---|---|
| Week 2 (n=28) | -0.6 ± 9.53 |
| Week 4 (n=28) | 0.2 ± 8.56 |
| Week 8 (n=25) | 0.7 ± 8.13 |
| Week 12 (n=21) | 1.1 ± 7.12 |
| Week 16 (n=21) | 0.1 ± 7.78 |
| Week 20 (n=20) | 0.8 ± 9.38 |
| Week 24 (n=20) | 0.8 ± 8.72 |
| Week 28 (n=20) | -0.5 ± 7.81 |
| Week 32 (n=20) | -0.8 ± 9.27 |
| Week 36 (n=20) | -0.4 ± 10.27 |
| Week 40 (n=20) | 0.7 ± 10.66 |
| Week 44 (n=19) | -1.2 ± 8.57 |
| Week 48 (n=19) | 1.3 ± 8.48 |
| Week 52 (n=18) | 3.0 ± 11.97 |
Heart rate was measured while the participant was sitting. n=the number of participants with available data at each time point.
| bpm | Adalimumab 80 mg |
|---|---|
| Week 2 (n=28) | -0.3 ± 11.94 |
| Week 4 (n=28) | 0.7 ± 12.78 |
| Week 8 (n=25) | -1.1 ± 9.48 |
| Week 12 (n=21) | -1.1 ± 11.59 |
| Week 16 (n=21) | -1.9 ± 9.56 |
| Week 20 (n=20) | -3.0 ± 8.68 |
| Week 24 (n=20) | -0.9 ± 13.15 |
| Week 28 (n=20) | -1.6 ± 11.30 |
| Week 32 (n=20) | -5.6 ± 11.95 |
| Week 36 (n=20) | -4.7 ± 12.88 |
| Week 40 (n=20) | -3.7 ± 13.88 |
| Week 44 (n=19) | -2.0 ± 10.78 |
| Week 48 (n=19) | -1.3 ± 15.53 |
| Week 52 (n=18) | -2.8 ± 11.80 |
n=the number of participants with available data at each time point.
| degrees Celcius | Adalimumab 80 mg |
|---|---|
| Week 2 (n=28) | -0.03 ± 0.558 |
| Week 4 (n=28) | -0.02 ± 0.571 |
| Week 8 (n=25) | -0.08 ± 0.569 |
| Week 12 (n=21) | -0.14 ± 0.606 |
| Week 16 (n=21) | -0.11 ± 0.558 |
| Week 20 (n=20) | -0.16 ± 0.545 |
| Week 24 (n=20) | -0.20 ± 0.701 |
| Week 28 (n=20) | -0.23 ± 0.716 |
| Week 32 (n=20) | -0.26 ± 0.762 |
| Week 36 (n=20) | -0.36 ± 0.476 |
| Week 40 (n=20) | -0.16 ± 0.555 |
| Week 44 (n=19) | -0.24 ± 0.472 |
| Week 48 (n=19) | -0.03 ± 0.781 |
| Week 52 (n=18) | -0.13 ± 0.717 |
An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs or TESAE) are defined as any event that began or worsened in severity after the first dose of study drug. The investigator assessed the relationship of each event to the use of study drug as either Reasonable possibility or No reasonable possibility of being related to study drug. For more details on adverse events please see the AE section below.
| participants | Adalimumab 80 mg |
|---|---|
| Any TEAE | 24 |
| TEAEs with reasonable possibility of being related | 5 |
| Any severe TEAE | 2 |
| TESAE | 8 |
| Any TEAE Leading to Discontinuation of Study | 4 |
| Death | 0 |
Collected over AEs were collected from the time of study drug administration until 70 days after last dose of study drug (60 weeks); SAEs were also collected from the time that informed consent was obtained until 70 days after last dose of study drug (up to 63 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab 80 mg | — | 8/28 (28.6%) | 21/28 (75%) |
| Event | Adalimumab 80 mg |
|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 4/28 |
| ILEUSGastrointestinal disorders | 1/28 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/28 |
| SMALL INTESTINAL ULCER HAEMORRHAGEGastrointestinal disorders | 1/28 |
| SUBILEUSGastrointestinal disorders | 1/28 |
| ANAL ABSCESSInfections and infestations | 1/28 |
| PNEUMONIA BACTERIALInfections and infestations | 1/28 |
| ALLERGIC TRANSFUSION REACTIONInjury, poisoning and procedural complications | 1/28 |
| Event | Adalimumab 80 mg |
|---|---|
| NASOPHARYNGITISInfections and infestations | 13/28 |
| RASHSkin and subcutaneous tissue disorders | 4/28 |
| HEADACHENervous system disorders | 3/28 |
| ANAEMIABlood and lymphatic system disorders | 2/28 |
| ABDOMINAL DISTENSIONGastrointestinal disorders | 2/28 |
| NAUSEAGastrointestinal disorders | 2/28 |
| PYREXIAGeneral disorders | 2/28 |
| BRONCHITISInfections and infestations | 2/28 |
| INFLUENZAInfections and infestations | 2/28 |
| OTITIS EXTERNAInfections and infestations | 2/28 |
| Age, Continuous(years) | Adalimumab 80 mg |
|---|---|
| Mean | 33.6 ± 10.09 |
| Sex: Female, Male(Participants) | Adalimumab 80 mg |
|---|---|
| Female | 12 |
| Male | 16 |
No study locations are listed for this record.
The record gives a start of Sep 2013, a primary completion of Mar 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab